Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity
about
Impact of New Genomic Technologies on Understanding Adverse Drug ReactionsGenetic polymorphisms of dihydropyrimidinase in a Japanese patient with capecitabine-induced toxicityDegradation Rate of 5-Fluorouracil in Metastatic Colorectal Cancer: A New Predictive Outcome Biomarker?Association of new deletion/duplication region at chromosome 1p21 with intellectual disability, severe speech deficit and autism spectrum disorder-like behavior: an all-in approach to solving the DPYD enigmaNew advances in DPYD genotype and risk of severe toxicity under capecitabine.Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analysesPharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 yearsOromandibular dystonia: a serious side effect of capecitabine.Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenaseThe influence of cytidine deaminase -33delC polymorphism on treatment outcome with high-dose cytarabine in Chinese patients with relapsed acute myeloid leukaemia.Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancerRace-associated biological differences among Luminal A breast tumors.DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan.Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance)Evaluation of an oral uracil loading test to identify DPD-deficient patients using a limited sampling strategy.Can GSTM1 and GSTT1 polymorphisms predict clinical outcomes of chemotherapy in gastric and colorectal cancers? A result based on the previous reports.Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer.Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.Prognostic information of a previously diagnosed sister is an independent prognosticator for a newly diagnosed sister with breast cancer.Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score.Nucleoside analogs: ready to enter the era of precision medicine?Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity.Identification of the Consistently Altered Metabolic Targets in Human Hepatocellular Carcinoma.Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines.Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity.Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteersThe Quest for Relevant Hepatocellular Carcinoma Biomarkers.Pharmacogenomics DNA Biomarkers in Colorectal Cancer: Current Update.DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update.Novel Genetic Variants in Carboxylesterase 1 Predict Severe Early-Onset Capecitabine-Related Toxicity.Pharmacokinetics and pharmacogenetics of capecitabine and its metabolites following replicate administration of two 500 mg tablet formulations.Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine.Early-Onset 5-Fluorouracil Toxicity in a Patient Negative for Dihydropyrimidine Dehydrogenase Mutations: The Clinical Course of Reversal with Uridine Triacetate.Quantitative Contribution of rs75017182 to Dihydropyrimidine Dehydrogenase mRNA Splicing and Enzyme Activity.Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies.Exome array analysis of adverse reactions to fluoropyrimidine-based therapy for gastrointestinal cancer.SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand.Germline pharmacogenomics of DPYD*9A (c.85T>C) variant in patients with gastrointestinal malignancies treated with fluoropyrimidines.'Toxgnostics': an unmet need in cancer medicine
P2860
Q26787099-DC52CEF3-D6BC-46C2-B9E3-4E0E6AB4CD9BQ28546743-5E88E663-32ED-4336-A466-975CA66D1141Q28554294-86EDF182-DF04-44BE-8684-323C3A3A6B75Q28596636-0A208DBE-7E77-4F20-B5F6-71D1985CDB49Q33648195-180AB5FA-D3EE-425D-A393-95F902B6A305Q33825180-0E21A8FD-FB38-49AC-94CA-4EACFE5F825FQ34008793-CA68E50B-928F-4857-B383-740136C31999Q35174812-5219D319-C7FE-4475-BD97-E90A804D2D9CQ35585759-326093C0-F64D-45D6-8527-6611AE3ECF61Q35691397-4AB44EEA-85CD-490F-B69F-DE22B02E1CF8Q35742555-D514C88F-405C-4D07-A5AD-1FA75FA9F3FCQ35922859-49B73FD3-7891-4608-80B8-F9FBE806E099Q36072520-35E637A1-7852-465E-9055-A84E21375808Q36535211-7953BF5E-B4A5-4776-BC63-A3E39FF35328Q36618144-C262E071-AB76-4171-9FA0-8833CF7D233CQ37042575-84D643C7-9DAF-49C6-8FC5-B9A9507597F1Q37706746-6F6500FA-24DB-4394-B6E0-564DD1CE1AC2Q38373831-096BC290-ACAE-4B51-A068-BCA064C20A6BQ38419595-C91C59C8-65EE-4810-B4C9-F4DAC55A4AB8Q38565029-FBB46F0A-89FC-4B35-8A39-7C93331A2EEBQ38842938-20F11258-279E-4917-8B0E-FA199AEEC5EDQ40068183-4EDDEA07-BA2C-4541-9D7C-5178B00FB63FQ40070808-08F2FC04-4A81-4649-85E9-78107155CD7EQ40811026-98C43E9C-2BE2-42AE-ACF3-D832EF02A1FCQ41442402-96919062-C799-482C-86CA-55C2E01373B2Q42210747-9498A1EE-BB9E-4FDE-AC61-980141430E1AQ42318180-CBCCB88C-0FA3-4097-AD4A-34CE3C3346D4Q42341394-91BBA140-AA52-49E0-8C1A-2EB070A9A93EQ42691338-B450EFE7-1E66-4975-A7E5-08CDB124E6B2Q47768032-99AB48DD-4A6C-42D8-9E54-59DA2D16D6F2Q48061495-22AB1C2B-A400-48A8-AE38-670961F78ECCQ50998446-2C1D079D-36AC-4A91-A62D-FD5BF65164EFQ51058654-6A6C0D34-92EC-4781-9B69-79F0AF4BE612Q51732084-1A2E6E59-855F-4235-A422-7C2B80912AB9Q53515176-40E3D790-05BC-4977-AD3E-A7295A60B7A9Q53621686-BD9A6F5F-8A5A-4440-8EB9-7B1EE2359532Q55268850-51F03568-2982-4876-8BDF-73AD10DEE17BQ55497899-AFFB3973-68CE-41AE-98FC-4C30F8B82CABQ55668963-7C35F088-19C0-4349-BBA4-2343CA88EA0AQ56675475-8573FEA5-4E22-432B-84CF-5F7DC2A56559
P2860
Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Pharmacogenetic variants in th ...... s of fluoropyrimidine toxicity
@en
type
label
Pharmacogenetic variants in th ...... s of fluoropyrimidine toxicity
@en
prefLabel
Pharmacogenetic variants in th ...... s of fluoropyrimidine toxicity
@en
P2093
P2860
P356
P1476
Pharmacogenetic variants in th ...... s of fluoropyrimidine toxicity
@en
P2093
A Corrigan
A Loganayagam
A M Marinaki
J D Sanderson
L Fairbanks
M Arenas Hernandez
P2860
P2888
P304
P356
10.1038/BJC.2013.262
P407
P577
2013-06-04T00:00:00Z